Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.

Bernard Escudier; Nathalie Lassau; Eric Angevin; Jean Charles Soria; Linda Chami; Michele Lamuraglia; Eric Zafarana; Veronique Landreau; Brian Schwartz; Eric Brendel

doi:10.1158/1078-0432.CCR-06-1432

Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.

Identifier:nobleid.org/w1/20260515/D73DF46B

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/D73DF46B.svg?ark=w1%2F20260515%2FD73DF46B)](https://nobleid.org/work/w1/20260515/D73DF46B)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.

Identifier:nobleid.org/w1/20260515/D73DF46B

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/D73DF46B.svg?ark=w1%2F20260515%2FD73DF46B)](https://nobleid.org/work/w1/20260515/D73DF46B)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work